Pharmaceutical intermediates
Abemaciclib Intermediates
4 pharmaceutical intermediates for Abemaciclib. Indication: HR-positive, HER2-negative Breast Cancer / Node-positive Breast Cancer, Advanced Breast Cancer / Metastatic Breast Cancer.
About Abemaciclib
- Originator
- Eli Lilly
- Indication
- HR-positive, HER2-negative Breast Cancer / Node-positive Breast Cancer, Advanced Breast Cancer / Metastatic Breast Cancer
- Approved Date
- 09/28/2017
- DS/DP
- 09/28/2031
Available intermediates
4 intermediates currently listed for Abemaciclib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 5-((4-Ethylpiperazin-1-yl)methyl)pyridin-2-amine | 1180132-17-5 | / | / |
| 1H-BenziMidazole, 6-(2-chloro-5-fluoro-4-pyriMidinyl)-4-fluoro-2-Methyl-1-(1-Methylethyl)- | 1231930-42-9 | / | / |
| 6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole | 1231930-33-8 | / | / |
| 2,4-Dichloro-5-fluoropyrimidine | 2927-71-1 | / | / |
Building toward Abemaciclib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →